Neuronetics, Inc. (NASDAQ:STIM) CFO Sells $41,536.35 in Stock

Neuronetics, Inc. (NASDAQ:STIM) CFO Stephen Furlong sold 10,845 shares of Neuronetics stock in a transaction dated Wednesday, February 12th. The shares were sold at an average price of $3.83, for a total transaction of $41,536.35. Following the sale, the chief financial officer now owns 471,727 shares of the company’s stock, valued at approximately $1,806,714.41. This represents a 2.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Stephen Furlong also recently made the following trade(s):

• On Monday, February 10th, Stephen Furlong sold 14,836 shares of Neuronetics stock. The stock was sold at an average price of $3.28, for a total transaction of $48,662.08.

Neuronetics Stock Up 11.8 %

Shares of NASDAQ STIM opened at $4.36 on Friday. The company has a quick ratio of 2.87, a current ratio of 3.16 and a debt-to-equity ratio of 4.90. The business’s 50 day moving average is $2.20 and its two-hundred day moving average is $1.41. Neuronetics, Inc. has a 52-week low of $0.52 and a 52-week high of $5.07. The firm has a market cap of $132.33 million, a price-to-earnings ratio of -3.54 and a beta of 2.17.

Hedge Funds Weigh In On Neuronetics

Several hedge funds have recently bought and sold shares of STIM. HighTower Advisors LLC grew its position in Neuronetics by 55.5% in the 3rd quarter. HighTower Advisors LLC now owns 245,982 shares of the company’s stock valued at $187,000 after acquiring an additional 87,816 shares in the last quarter. GSA Capital Partners LLP boosted its stake in shares of Neuronetics by 64.5% in the third quarter. GSA Capital Partners LLP now owns 78,642 shares of the company’s stock valued at $60,000 after purchasing an additional 30,837 shares during the period. Landscape Capital Management L.L.C. acquired a new position in shares of Neuronetics in the third quarter valued at approximately $53,000. JPMorgan Chase & Co. increased its stake in Neuronetics by 10,954.1% during the 4th quarter. JPMorgan Chase & Co. now owns 54,939 shares of the company’s stock worth $88,000 after buying an additional 54,442 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in Neuronetics by 2.8% during the 4th quarter. Geode Capital Management LLC now owns 314,076 shares of the company’s stock worth $506,000 after buying an additional 8,466 shares in the last quarter. Institutional investors and hedge funds own 53.59% of the company’s stock.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.